Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Immunol. 2021 Apr 12;12:621935. doi: 10.3389/fimmu.2021.621935. eCollection 2021.
We compared the effectiveness and safety of pegylated granulocyte colony-stimulating factor (peg-G-CSF) vs. non-peg-G-CSF for hematopoietic stem cell mobilization in allogeneic hematopoietic stem cell transplantation in a real-world setting. We included 136 consecutive healthy donors treated with non-peg-G-CSF (n = 53) or peg-G-CSF (n = 83), and 125 consecutive recipients (n = 42 and 83, respectively) in this study. All harvesting was completed successfully. No significant difference in leukapheresis number and adverse events frequency was observed, nor were there severe adverse events leading to discontinuation of mobilization. The leukapheresis products mobilized by peg-G-CSF had higher total nucleated cells (p < 0.001), monocytic myeloid-derived suppressor cells (p < 0.001), granulocytic myeloid-derived suppressor cells (p = 0.004) and B cells (p = 0.019). CD34+ cells and other lymphocyte subsets (T cells, regulatory T cells, natural killer [NK] cells, etc.) were similar in both apheresis products. Patients who received grafts mobilized by peg-G-CSF exhibited a lower incidence of grade III-IV acute graft-versus-host disease (p = 0.001). The 1-year cumulative incidence of chronic graft-versus-host disease and relapse, 1-year probability of graft-versus-host disease-free relapse-free survival, and overall survival did not differ significantly between subgroups. Our results suggest that collecting allogeneic stem cells after the administration of peg-G-CSF is feasible and safe. Peg-G-CSF mobilized grafts may reduce severe acute graft-versus-host disease compared with non-peg-G-CSF mobilized grafts after allogeneic stem cell transplantation. The beneficial effects of a peg-G-CSF graft might be mediated by increased numbers of monocytic myeloid-derived suppressor cells.
我们比较了在同种异体造血干细胞移植中,使用聚乙二醇化粒细胞集落刺激因子(peg-G-CSF)与非 peg-G-CSF 进行造血干细胞动员的效果和安全性。在这项研究中,我们纳入了 136 例连续的接受非 peg-G-CSF(n=53)或 peg-G-CSF(n=83)治疗的健康供者,以及 125 例连续的接受移植的受者(分别为 n=42 和 83)。所有采集均成功完成。白细胞分离次数和不良反应频率无显著差异,也没有导致动员停止的严重不良事件。peg-G-CSF 动员的白细胞分离产物中总核细胞(p<0.001)、单核细胞来源的髓系抑制细胞(p<0.001)、粒细胞来源的髓系抑制细胞(p=0.004)和 B 细胞(p=0.019)更高。两种白细胞分离产物中的 CD34+细胞和其他淋巴细胞亚群(T 细胞、调节性 T 细胞、自然杀伤细胞等)相似。接受 peg-G-CSF 动员的移植物的 III-IV 级急性移植物抗宿主病发生率较低(p=0.001)。慢性移植物抗宿主病和复发的 1 年累积发生率、1 年无移植物抗宿主病-无复发存活率和总生存率在亚组之间无显著差异。我们的结果表明,在给予 peg-G-CSF 后采集同种异体干细胞是可行和安全的。与非 peg-G-CSF 动员的移植物相比,peg-G-CSF 动员的移植物可能会降低同种异体干细胞移植后严重的急性移植物抗宿主病。peg-G-CSF 移植物的有益效果可能是通过增加单核细胞来源的髓系抑制细胞的数量介导的。